Are Sleeping Pills Bad for Your Heart?

Sleeping pills as a category are not uniformly harmful to the heart, but several widely used types carry real cardiovascular risks that range from elevated blood pressure and arrhythmias to increased odds of heart failure. The picture varies sharply depending on which drug you take, how often you take it, and what heart-related conditions you already have. Complicating things further, untreated insomnia itself is a cardiovascular risk factor, which makes the decision less straightforward than a simple “yes, they’re bad” or “no, they’re fine.”

Not All Sleeping Pills Work the Same Way

The term “sleeping pill” covers a surprisingly wide range of drugs with very different mechanisms. Older benzodiazepines like diazepam and temazepam work by amplifying the brain’s main inhibitory signaling system. So-called Z-drugs like zolpidem and zopiclone target many of the same receptors but are more selective. Over-the-counter options, typically antihistamines like diphenhydramine, block histamine receptors to make you drowsy. Newer prescription options include orexin receptor antagonists (like suvorexant and lemborexant), which block wakefulness-promoting signals, and melatonin receptor agonists (like ramelteon), which nudge your internal clock toward sleep. Each of these classes interacts with the cardiovascular system differently, and lumping them together hides important distinctions.

Benzodiazepines Carry the Clearest Heart Risks

Among sleeping pills studied for cardiovascular effects, benzodiazepines have the most concerning track record. A large study of insomnia patients found that benzodiazepine use was significantly associated with increased risks of coronary heart disease, heart failure, and cardiovascular death.¹ Regular use, rather than occasional use, drove most of that elevated risk.²

The mechanisms behind this link are not fully settled, but benzodiazepines are known to depress the central nervous system broadly, which can affect heart rate regulation, respiratory drive, and autonomic balance. They also tend to be prescribed for longer stretches than intended, and chronic use compounds whatever cardiovascular effects exist. For people already living with heart disease or heart failure, the combination of respiratory depression and reduced cardiac responsiveness is an especially poor fit.

Z-Drugs Are Not as Clean as Once Thought

When zolpidem, zopiclone, and related Z-drugs were introduced, they were marketed as safer successors to benzodiazepines. From a cardiovascular standpoint, the picture is more nuanced than that early reputation suggests. A review of the evidence found that Z-drugs may carry relatively less risk than benzodiazepines and anxiolytics, and that zolpidem in particular may even show lower mortality in some adjusted analyses.³ But “relatively less risk” is not the same as “safe.”

A study of older women with sleep disturbances found that Z-drug use was associated with roughly a 35% higher risk of cardiovascular disease and about a 38% higher risk of dying from any cause.⁴ And a nationwide population-based study in Taiwan found that zolpidem use was associated with nearly double the risk of cardiac arrhythmia, with particularly elevated rates of paroxysmal tachycardia and atrial flutter.⁵ Arrhythmias are worth paying attention to because they can cascade into more serious events, including stroke and sudden cardiac death, particularly in people who already have structural heart problems.

The disconnect between adjusted mortality models (where zolpidem looks relatively benign) and arrhythmia studies (where it looks worrisome) is a good example of why the overall evidence on sleeping pills and heart health feels messy. Different studies measure different endpoints, in different populations, over different timeframes. The honest summary is that Z-drugs sit somewhere between benzodiazepines and newer agents on the cardiovascular risk spectrum, and they deserve more caution than their “safer alternative” branding suggests.

Over-the-Counter Sleep Aids and Stroke

Many people assume that if a sleep aid is available without a prescription, it must be gentle on the body. The data on cardiovascular risk challenges that assumption in a surprising way. A large U.S. study called REGARDS, which tracked over 16,000 adults over several years, found that over-the-counter sleep medication use was associated with a significantly increased risk of stroke. People who used OTC sleep aids one to 14 days per month had a 46% higher stroke risk, and those who used them 15 or more days per month had a 65% higher risk, following a clear dose-response pattern.⁶

Interestingly, the same study found no significant association between prescription sleep medications and stroke risk. The authors speculated that OTC users may be less likely to have their sleep problems properly evaluated and treated, and may also be using antihistamines with anticholinergic properties that affect blood vessel function. Diphenhydramine, the most common active ingredient in OTC sleep aids, has known effects on heart rate and, at higher doses, can cause QT prolongation. For people reaching for an OTC sleep aid several times a week, these findings are worth knowing about.

Orexin Receptor Antagonists Look More Heart-Friendly

The newest class of prescription sleep medications works by blocking orexin, a neuropeptide that promotes wakefulness. Suvorexant (Belsomra) and lemborexant (Dayvigo) are the most widely prescribed examples. Early evidence suggests their cardiovascular profile is more favorable than older options. A study of patients who had just undergone coronary artery bypass surgery found that suvorexant did not worsen cardiac function, blood pressure, heart rate, or any measured respiratory parameter compared to controls.⁷

That study focused on a post-surgical population, which is a demanding test case: these patients have freshly manipulated hearts and are closely monitored for hemodynamic instability. The fact that suvorexant passed this test without any significant changes to cardiac output or blood pressure is encouraging. Researchers have also been investigating suvorexant specifically in heart failure patients with sleep-disordered breathing, suggesting enough clinical optimism about its cardiac safety to justify trials in a vulnerable population.⁵ The long-term cardiovascular data on DORAs is still thin compared to decades of data on benzodiazepines and Z-drugs, but nothing alarming has surfaced so far.

Melatonin and Melatonin Receptor Agonists

Melatonin, available over the counter in most countries, is often treated as a separate category from “real” sleeping pills, but it acts on the same system that prescription melatonin receptor agonists like ramelteon target. From a heart perspective, melatonin is one of the more interesting sleep aids because it appears to offer some cardiovascular protection rather than risk. Research across both animal and human studies has found evidence that melatonin reduces cardiac damage during ischemia-reperfusion events (the kind of injury that occurs during and after a heart attack), acts as an antioxidant in cardiac tissue, and may help prevent the heart muscle thickening that leads to heart failure.⁸

A study looking at heart rate variability, which is a marker of how well the autonomic nervous system regulates the heart, found that treatment with agomelatine (a melatonergic antidepressant) increased high-frequency heart rate variability, a change associated with better cardiac autonomic tone.⁹ When the same drug was combined with sedative-hypnotics, however, the results shifted: both low- and high-frequency heart rate variability decreased, and the ratio between them tilted in a less favorable direction. That finding hints at a broader theme in this research: combining sleep medications can produce cardiovascular effects that neither drug produces alone.

Untreated Insomnia Is a Heart Risk Too

Any discussion of whether sleeping pills hurt the heart has to grapple with a fundamental confound: poor sleep itself is bad for the heart. Multiple prospective studies and meta-analyses have shown that insomnia, sleeping less than seven hours, or sleeping more than nine hours are all associated with increased risks of high blood pressure, metabolic syndrome, heart attack, heart failure, arrhythmias, and cardiovascular death.³ When researchers observe that sleeping pill users have worse cardiovascular outcomes, it is genuinely difficult to separate the effect of the drug from the effect of the underlying sleep problem that prompted the prescription.

This confounding problem has been acknowledged for decades. An early large-scale epidemiological study from the late 1970s, involving over a million participants, found that people who reported using sleeping pills “often” had about 1.5 times the mortality of nonusers, but the authors themselves cautioned that their results did not prove that reducing hypnotic prescriptions would lower mortality.¹⁰ More recent reviews have echoed this concern, noting that while observational studies and meta-analyses point toward increased mortality risk with anxiolytics and hypnotics, bias from confounding and high study heterogeneity may be distorting the picture.³

In practical terms, this means the choice isn’t simply “take a sleeping pill and risk your heart” versus “don’t take one and protect it.” For someone with chronic insomnia that is driving up their blood pressure or worsening their metabolic health, leaving it untreated carries its own cardiac price. The real question is which treatment approach yields the best net outcome for your cardiovascular system.

The Blood Pressure Paradox

One counterintuitive finding complicates the straightforward “sleeping pills are bad for your heart” narrative. A large cross-sectional study found that among people who were not taking blood pressure medication, frequent sleeping pill users actually had significantly lower systolic blood pressure, diastolic blood pressure, and pulse pressure compared to nonusers.¹¹ The relationship followed a dose-response pattern: the more frequently someone used sleeping pills, the lower their blood pressure tended to be. This held across different age groups.

At the same time, the study found that people with hypertension were more likely to be using sleeping pills in the first place, which makes sense because high blood pressure and poor sleep are closely linked. The authors suggested that sleeping pills may help reduce blood pressure by improving sleep quality, which in turn lowers sympathetic nervous system activation. If you sleep better, your body spends more of the night in a restorative, low-stress state, and that shows up in blood pressure readings. This is one of those findings that highlights why the cardiovascular story around sleeping pills resists simple answers: the same drugs that are associated with arrhythmia risk in some populations may be helping with blood pressure control in others.

Sleep Apnea Makes Everything Riskier

If you have obstructive sleep apnea, whether diagnosed or not, sedating sleep medications carry additional cardiovascular danger. A Cochrane systematic review examined the effects of sedating medications on people with known obstructive sleep apnea and found that certain agents shifted the pattern of breathing events during sleep: while they sometimes reduced obstructive apneas, they increased central apneas, which are episodes where the brain temporarily stops sending the signal to breathe.¹² Central apneas are particularly concerning from a cardiac perspective because they are associated with drops in blood oxygen, spikes in sympathetic nervous system activity, and worsening of the cardiac strain that sleep apnea already produces.

Sleep apnea itself is one of the strongest sleep-related risk factors for cardiovascular disease, contributing to high blood pressure, atrial fibrillation, heart failure, and stroke. When a sleeping pill adds respiratory depression on top of airways that are already collapsing, the cardiovascular system takes a double hit: oxygen drops lower, recovery between apneas takes longer, and the heart works harder to compensate. For anyone who snores heavily, has been told they stop breathing at night, or who wakes unrefreshed despite what should be enough sleep, a sleep evaluation matters more than picking the right pill.

Behavioral Alternatives That Help the Heart

Cognitive behavioral therapy for insomnia, often abbreviated CBT-I, is recommended as the first-line treatment for chronic insomnia by virtually every major sleep medicine organization. It involves structured changes to sleep habits, stimulus control, sleep restriction, and cognitive techniques to break the anxiety-insomnia cycle. Unlike pills, CBT-I addresses the root causes of insomnia, and the cardiovascular evidence is encouraging in its own right.

A systematic review and meta-analysis of behavioral sleep interventions found that CBT-I and sleep hygiene programs lowered systolic blood pressure by an average of about 3.4 mmHg.¹³ That may sound modest, but in population terms a reduction of that size translates to meaningful decreases in stroke and heart attack rates. And because the benefits come from better sleep rather than from a drug with its own side-effect profile, there is no arrhythmia risk, no respiratory depression, and no dependency concern. The main limitation of CBT-I is access: it requires multiple sessions with a trained therapist, though digital CBT-I programs have been expanding availability. For someone whose insomnia is genuinely hurting their heart health, the effort of completing a CBT-I program may pay dividends that no pill can match.

Who Should Be Most Cautious

Certain groups face amplified cardiovascular risk from sleeping pills. Older adults are prescribed hypnotics at the highest rates and are also the most vulnerable to their cardiac and respiratory effects. The study showing Z-drug-associated cardiovascular risk was specifically conducted in older women, and age appeared to magnify the associations in several of the blood pressure analyses.⁴ People with existing heart failure, coronary artery disease, or a history of arrhythmias are another group that should approach sleep medications with extra care, particularly benzodiazepines and Z-drugs.

People taking cardiac medications also face potential drug interactions. Many sleep aids are metabolized by the same liver enzymes that process common heart drugs, including certain statins, blood thinners, and antiarrhythmics. Benzodiazepines and Z-drugs in particular can potentiate the effects of other central nervous system depressants, and combining them with opioids (which some cardiac patients take for pain management) dramatically increases the risk of respiratory depression. If you are already on heart medications and considering a sleep aid, the conversation with your doctor matters more than any general-audience article can capture, because the interaction risk depends on your specific drug regimen.

Frequency and Duration of Use

One of the clearest patterns across the evidence is that the cardiovascular risks of sleeping pills scale with how often and how long you use them. The REGARDS stroke study showed a stepwise increase in risk with more frequent OTC sleep aid use.⁶ The benzodiazepine data showed that regular users, not occasional users, had the elevated risk of coronary heart disease and heart failure.² Even the blood pressure benefit seen with sleeping pills followed a frequency-dependent pattern, with more frequent use linked to larger reductions.¹¹

The practical takeaway is that occasional, short-term use of most sleeping pills is far less likely to cause lasting cardiac harm than nightly, long-term use. Sleeping pills were designed as short-term aids, typically recommended for two to four weeks, but in practice many people use them for months or years. If you have been taking a sleep aid nightly for an extended period, the cardiovascular conversation is worth having with a clinician who can evaluate whether your net risk-benefit balance has shifted. In many cases, a plan to taper the medication while introducing behavioral strategies like CBT-I offers the best cardiac outlook.

1
PubMed. Hypnotic use and the risk of cardiovascular diseases in insomnia patients
2
European Journal of Preventive Cardiology. Hypnotic use and the risk of cardiovascular diseases in insomnia patients
3
PubMed. Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
4
PubMed. The association of hypnotics with incident cardiovascular disease and mortality in older women with sleep disturbances
5
PubMed Central. Zolpidem use and the risk of arrhythmia: A nationwide population-based cohort study in Taiwan
6
PubMed Central. Over-the-Counter and Prescription Sleep Medication and Incident Stroke: The REGARDS Study
7
Journal of Coronary Artery Disease. Safety of Orexin Receptor Antagonist on Cardiac and Respiratory Function in Patients who Underwent Off-pump Coronary Artery Bypass Grafting
8
PubMed Central. Evidence for the Benefits of Melatonin in Cardiovascular Disease
9
PubMed. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk
10
JAMA Psychiatry. Short and Long Sleep and Sleeping Pills: Is Increased Mortality Associated?
11
PubMed Central. Lower blood pressure and smaller pulse pressure in sleeping pill users
12
Cochrane Database of Systematic Reviews. Effects of opioid, hypnotic and sedating medications on obstructive sleep apnoea in adults with known OSA
13
European Heart Journal Open. Effect of behavioural sleep interventions on blood pressure, heart rate, and heart rate variability in adults with poor sleep health: a systematic review, meta-analysis, and meta-regression analysis